Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial

BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce the risk of atrial fibrillation (AF) in patients with heart failure (HF) and a reduced ejection fraction. The efficacy of MRAs for AF prevention in patients with HF and a preserved ejection fraction (HFpEF) is unclear. OBJECTIVES: We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Neefs, Jolien, van den Berg, Nicoline W. E., Krul, Sébastien P. J., Boekholdt, S. Matthijs, de Groot, Joris R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978290/
https://www.ncbi.nlm.nih.gov/pubmed/31214914
http://dx.doi.org/10.1007/s40256-019-00353-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978290/
https://www.ncbi.nlm.nih.gov/pubmed/31214914
http://dx.doi.org/10.1007/s40256-019-00353-5

Ejemplares similares